COX-2 and PGE2-dependent immunomodulation in breast cancer

Prostaglandins and Other Lipid Mediators

Volumn 96, Issue 1-4, 2011, Pages 14-20

  Chen, Edward P ^a   Smyth, Emer M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast cancer; COX 2; Immune suppression; Macrophage polarization; Microenvironment; Myeloid derived suppressor cells; PGE2; Regulatory T lymphocytes

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; ROFECOXIB; ANTINEOPLASTIC AGENT; CYTOKINE; PTGS2 PROTEIN, HUMAN;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BONE MARROW CELL; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INVASION; CARCINOGENESIS; CELL FUNCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INFLAMMATORY INFILTRATE; LUNG CARCINOMA; MACROPHAGE; MAST CELL; MESOTHELIOMA; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; POLARIZATION; PROSTAGLANDIN METABOLISM; REGULATORY T LYMPHOCYTE; REVIEW; STROMA CELL; SUPPRESSOR CELL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; BREAST TUMOR; CARCINOMA; CELL TRANSFORMATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MOUSE; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 81155139720     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2011.08.005     Document Type: Review

References (86)

1. E.M. Smyth, T. Grosser, M. Wang, Y. Yu, and G.A. FitzGerald Prostanoids in health and disease J Lipid Res 50 Suppl. 2009 S423 S428
2. D. Wang, and R.N. Dubois Eicosanoids and cancer Nat Rev Cancer 10 3 2010 181 193
3. H. Kuper, H.O. Adami, and D. Trichopoulos Infections as a major preventable cause of human cancer J Intern Med 248 3 2000 171 183 (Pubitemid 33702479)
4. L.R. Howe Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer Breast Cancer Res 9 4 2007 210
5. R.E. Harris Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung Inflammopharmacology 17 2 2009 55 67
6. R.E. Harris, R.T. Chlebowski, and R.D. Jackson Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative Cancer Res 63 18 2003 6096 6101 (Pubitemid 37187516)
7. N.R. Cook, I.M. Lee, and J.M. Gaziano Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial JAMA 294 1 2005 47 55 (Pubitemid 41002838)
8. M.D. Holmes, W.Y. Chen, L. Li, E. Hertzmark, D. Spiegelman, and S.E. Hankinson Aspirin intake and survival after breast cancer J Clin Oncol 28 9 2010 1467 1472
9. T.M. Brasky, M.R. Bonner, and K.B. Moysich Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study Cancer Causes Control 21 9 2010 1503 1512
10. P.M. Rothwell, F.G. Fowkes, J.F. Belch, H. Ogawa, C.P. Warlow, and T.W. Meade Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 9759 2011 31 41
11. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674
12. J.A. Joyce, and J.W. Pollard Microenvironmental regulation of metastasis Nat Rev Cancer 9 4 2009 239 252
13. D. Kamei, M. Murakami, Y. Nakatani, Y. Ishikawa, T. Ishii, and I. Kudo Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis J Biol Chem 278 21 2003 19396 19405 (Pubitemid 36799335)
14. M. Murakami, H. Naraba, and T. Tanioka Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2 J Biol Chem 275 42 2000 32783 32792
15. H.H. Tai, C.M. Ensor, M. Tong, H. Zhou, and F. Yan Prostaglandin catabolizing enzymes Prostaglandins Other Lipid Mediat 6 8-69 2002 483 493 (Pubitemid 35247416)
16. G. Reid, P. Wielinga, and N. Zelcer The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs Proc Natl Acad Sci USA 100 16 2003 9244 9249 (Pubitemid 37033914)
17. G. Singh-Ranger, M. Salhab, and K. Mokbel The role of cyclooxygenase-2 in breast cancer: review Breast Cancer Res Treat 109 2 2008 189 198 (Pubitemid 351644840)
18. A. Greenhough, H.J. Smartt, and A.E. Moore The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis 30 3 2009 377 386
19. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 1 2000 57 70 (Pubitemid 30046295)
20. M.D. Castellone, H. Teramoto, B.O. Williams, K.M. Druey, and J.S. Gutkind Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis Science 310 5753 2005 1504 1510 (Pubitemid 41746348)
21. D. Wang, H. Wang, and Q. Shi Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta Cancer Cell 6 3 2004 285 295 (Pubitemid 39222041)
22. H. Sheng, J. Shao, J.D. Morrow, R.D. Beauchamp, and R.N. DuBois Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells Cancer Res 58 2 1998 362 366 (Pubitemid 28047080)
23. R. Pai, B. Soreghan, I.L. Szabo, M. Pavelka, D. Baatar, and A.S. Tarnawski Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy Nat Med 8 3 2002 289 293 (Pubitemid 34250108)
24. H. Fujino, K. Toyomura, X.B. Chen, J.W. Regan, T. Murayama, and Prostaglandin E regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells Biochem Pharmacol 81 3 2011 379 387
25. F. Cianchi, C. Cortesini, and P. Bechi Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer Gastroenterology 121 6 2001 1339 1347 (Pubitemid 33140451)
26. H. Amano, I. Hayashi, and H. Endo Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth J Exp Med 197 2 2003 221 232 (Pubitemid 36152316)
27. H. Amano, Y. Ito, and T. Suzuki Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis Cancer Sci 100 12 2009 2318 2324
28. R. Pai, I.L. Szabo, B.A. Soreghan, S. Atay, H. Kawanaka, and A.S. Tarnawski PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways Biochem Biophys Res Commun 286 5 2001 923 928 (Pubitemid 32924860)
29. S. Nakatsugi, T. Ohta, and T. Kawamori Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP)-induced mammary gland carcinogenesis in rats Jpn J Cancer Res 91 9 2000 886 892
30. R. Hamid, J. Singh, B.S. Reddy, and L.A. Cohen Inhibition by dietary menhaden oil of cyclooxygenase-1 and -2 in N-nitrosomethylurea-induced rat mammary tumors Int J Oncol 14 3 1999 523 528
31. K. Subbaramaiah, L.R. Howe, and E.R. Port HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism Cancer Res 66 10 2006 5504 5511 (Pubitemid 43844979)
32. S.H. Chang, Y. Ai, R.M. Breyer, T.F. Lane, and T. Hla The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia Cancer Res 65 11 2005 4496 4499 (Pubitemid 40740782)
33. C.H. Liu, S.H. Chang, and K. Narko Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice J Biol Chem 276 21 2001 18563 18569
34. R.E. Harris, G.A. Alshafie, H. Abou-Issa, and K. Seibert Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor Cancer Res 60 8 2000 2101 2103 (Pubitemid 30225166)
35. P. Kubatka, I. Ahlers, and E. Ahlersova Chemoprevention of mammary carcinogenesis in female rats by rofecoxib Cancer Lett 202 2 2003 131 136 (Pubitemid 37485885)
36. S. Lanza-Jacoby, S. Miller, and J. Flynn The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice Cancer Epidemiol Biomarkers Prev 12 12 2003 1486 1491 (Pubitemid 38031753)
37. S.S. Qadri, J.H. Wang, and J.C. Coffey Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition Ann Thorac Surg 79 3 2005 990 995 discussion-5 (Pubitemid 40288763)
38. L.R. Howe, S.H. Chang, and K.C. Tolle HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice Cancer Res 65 21 2005 10113 10119 (Pubitemid 41541494)
39. S.H. Chang, C.H. Liu, and R. Conway Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression Proc Natl Acad Sci USA 101 2 2004 591 596 (Pubitemid 38084681)
40. N. Markosyan, E. Chen, and V. Ndong Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors Carcinogenesis 2011 10.1093/carcin/bgr134
41. K. Polyak, and R. Kalluri The role of the microenvironment in mammary gland development and cancer Cold Spring Harb Perspect Biol 2 11 2010 a003244
42. M. Hu, and K. Polyak Microenvironmental regulation of cancer development Curr Opin Genet Dev 18 1 2008 27 34 (Pubitemid 351694443)
43. D.S. Dolberg, and M.J. Bissell Inability of Rous sarcoma virus to cause sarcomas in the avian embryo Nature 309 5968 1984 552 556 (Pubitemid 14109376)
44. K.E. de Visser, A. Eichten, and L.M. Coussens Paradoxical roles of the immune system during cancer development Nat Rev Cancer 6 1 2006 24 37 (Pubitemid 43053650)
45. J.E. Talmadge, M. Donkor, and E. Scholar Inflammatory cell infiltration of tumors: Jekyll or Hyde Cancer Metastasis Rev 26 3-4 2007 373 400 (Pubitemid 350115102)
46. D.G. DeNardo, J.B. Barreto, and P. Andreu CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages Cancer Cell 16 2 2009 91 102
47. S. Gordon, and P.R. Taylor Monocyte and macrophage heterogeneity Nat Rev Immunol 5 12 2005 953 964 (Pubitemid 41746764)
48. E. Eruslanov, I. Daurkin, J. Ortiz, J. Vieweg, and S. Kusmartsev Pivotal advance: tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE catabolism in myeloid cells J Leukoc Biol 88 5 2010 839 848
49. W.F. Doe, and P.M. Henson Macrophage stimulation by bacterial lipopolysaccharides. I. Cytolytic effect on tumor target cells J Exp Med 148 2 1978 544 556 (Pubitemid 8392715)
50. A.H. Ding, C.F. Nathan, and D.J. Stuehr Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production J Immunol 141 7 1988 2407 2412
51. M. Stein, S. Keshav, N. Harris, and S. Gordon Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation J Exp Med 176 1 1992 287 292
52. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends Immunol 23 11 2002 549 555 (Pubitemid 35223554)
53. C.D. Mills, K. Kincaid, J.M. Alt, M.J. Heilman, and A.M. Hill M-1/M-2 macrophages and the Th1/Th2 paradigm J Immunol 164 12 2000 6166 6173 (Pubitemid 30408793)
54. P.C. Rodriguez, D.G. Quiceno, and A.C. Ochoa l-Arginine availability regulates T-lymphocyte cell-cycle progression Blood 109 4 2007 1568 1573 (Pubitemid 46239590)
55. M.R. Young, E. Wheeler, and M. Newby Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma J Natl Cancer Inst 76 4 1986 745 750 (Pubitemid 16110081)
56. Y. Hui, E. Ricciotti, and I. Crichton Targeted deletions of cyclooxygenase-2 and atherogenesis in mice Circulation 121 24 2010 2654 2660
57. A. Saccani, T. Schioppa, and C. Porta p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance Cancer Res 66 23 2006 11432 11440 (Pubitemid 46009975)
58. P.J. Knudsen, C.A. Dinarello, and T.B. Strom Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate J Immunol 137 10 1986 3189 3194 (Pubitemid 17181688)
59. S. Bailly, B. Ferrua, M. Fay, and M.A. Gougerot-Pocidalo Differential regulation of IL 6, IL 1 A, IL 1 beta and TNF alpha production in LPS-stimulated human monocytes: role of cyclic AMP Cytokine 2 3 1990 205 210
60. T.J. Standiford, S.L. Kunkel, M.W. Rolfe, H.L. Evanoff, R.M. Allen, and R.M. Strieter Regulation of human alveolar macrophage- and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone Am J Respir Cell Mol Biol 6 1 1992 75 81
61. G. Strassmann, V. Patil-Koota, F. Finkelman, M. Fong, and T. Kambayashi Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2 J Exp Med 180 6 1994 2365 2370 (Pubitemid 24351620)
62. F. D'Acquisto, L. Sautebin, T. Iuvone, M. Di Rosa, and R. Carnuccio Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-kappaB activation in J774 macrophages FEBS Lett 440 1-2 1998 76 80 (Pubitemid 28558739)
63. W.K. Wu, O.P. Llewellyn, D.O. Bates, L.B. Nicholson, and A.D. Dick IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia Immunobiology 215 9-10 2010 796 803
64. M.R. Young, M. Newby, and H.T. Wepsic Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors Cancer Res 47 1 1987 100 105 (Pubitemid 17002105)
65. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat Rev Immunol 9 3 2009 162 174
66. R.M. Bingisser, P.A. Tilbrook, P.G. Holt, and U.R. Kees Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway J Immunol 160 12 1998 5729 5734 (Pubitemid 28298028)
67. O. Harari, and J.K. Liao Inhibition of MHC II gene transcription by nitric oxide and antioxidants Curr Pharm Des 10 8 2004 893 898 (Pubitemid 38380067)
68. L. Rivoltini, M. Carrabba, and V. Huber Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction Immunol Rev 188 2002 97 113 (Pubitemid 35398868)
69. V. Bronte, P. Serafini, and C. De Santo IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice J Immunol 170 1 2003 270 278 (Pubitemid 36026149)
70. S. Nagaraj, K. Gupta, and V. Pisarev Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer Nat Med 13 7 2007 828 835 (Pubitemid 47038194)
71. P. Sinha, V.K. Clements, A.M. Fulton, and S. Ostrand-Rosenberg Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells Cancer Res 67 9 2007 4507 4513 (Pubitemid 46815102)
72. X. Xiang, A. Poliakov, and C. Liu Induction of myeloid-derived suppressor cells by tumor exosomes Int J Cancer 124 11 2009 2621 2633
73. P.C. Rodriguez, C.P. Hernandez, and D. Quiceno Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma J Exp Med 202 7 2005 931 939 (Pubitemid 41396893)
74. Y. Zhang, Q. Liu, M. Zhang, Y. Yu, X. Liu, and X. Cao Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2 J Immunol 182 6 2009 3801 3808
75. J.E. Talmadge, K.C. Hood, L.C. Zobel, L.R. Shafer, M. Coles, and B. Toth Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion Int Immunopharmacol 7 2 2007 140 151 (Pubitemid 46043318)
76. J.D. Veltman, M.E. Lambers, and M. van Nimwegen COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function BMC Cancer 10 2010 464
77. S. Sakaguchi, and Regulatory T cells: key controllers of immunologic self-tolerance Cell 101 5 2000 455 458
78. D.J. Campbell, and M.A. Koch Phenotypical and functional specialization of FOXP3+ regulatory T cells Nat Rev Immunol 11 2 2011 119 130
79. L.L. Feng, and X. Wang Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy Chin Med J (Engl) 123 22 2010 3334 3342
80. X.L. Yuan, L. Chen, and M.X. Li Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner Clin Immunol 134 3 2010 277 288
81. J. Yokokawa, V. Cereda, and C. Remondo Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer Clin Cancer Res 14 4 2008 1032 1040 (Pubitemid 351302548)
82. S. Yaqub, K. Henjum, and M. Mahic Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner Cancer Immunol Immunother 57 6 2008 813 821 (Pubitemid 351660125)
83. S. Sharma, S.C. Yang, and L. Zhu Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer Cancer Res 65 12 2005 5211 5220 (Pubitemid 40827331)
84. B.P. Lee, S.C. Juvet, and L. Zhang Prostaglandin E2 signaling through E prostanoid receptor 2 impairs proliferative response of double negative regulatory T cells Int Immunopharmacol 9 5 2009 534 539
85. H. Chen, J. Qin, and P. Wei Effects of leukotriene B4 and prostaglandin E2 on the differentiation of murine Foxp3+ T regulatory cells and Th17 cells Prostaglandins Leukot Essent Fatty Acids 80 4 2009 195 200
86. Z.G. Fridlender, J. Sun, and S. Kim Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN Cancer Cell 16 3 2009 183 194